Fintel reports that on February 13, 2025, Scotiabank initiated coverage of Viking Therapeutics (NasdaqCM:VKTX) with a Sector ...

H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Viking Therapeutics (VKTX – Research Report) today and set a price target ...

In trading on Thursday, shares of Viking Therapeutics Inc (Symbol: VKTX) entered into oversold territory, hitting an RSI reading of 29.7, after changing hands as low as $28.81 per share.

VKTX stock opened at $30.48 on Thursday. Viking Therapeutics has a fifty-two week low of $28.64 and a fifty-two week high of $99.41. The business’s 50-day moving average is $37.97 and its two ...

H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Viking Therapeutics (VKTX – Research Report) today and set a price target of $102.00. The company’s shares closed yesterday ...

Weight-loss drugs have been popular over the past couple of years, and Hims & Hers Health Inc (NYSE:HIMS), Novo Nordisk A/S ( NYSE:NVO), and Viking Therapeutics Inc (NASDAQ:VKTX) are among the most ...

Three of VBK's underlying holdings with notable upside to their analyst target prices are Viking Therapeutics Inc (Symbol: VKTX), PACS Group Inc (Symbol: PACS), and Crinetics Pharmaceuticals Inc ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...